



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 9, 2020

Christopher Bunka  
Chief Executive Officer  
Lexaria Bioscience Corp.  
#100 – 740 McCurdy Road  
Kelowna, British Columbia V1X 2P7

**Re: Lexaria Bioscience Corp.  
Registration Statement on Form S-1  
Filed June 3, 2020  
File No. 333-238915**

Dear Mr. Bunka:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Laura Nicholson, Special Counsel, at (202) 551-3584 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Energy & Transportation

cc: Avital Perlman